Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors.  | Dexcom said Smart Basal is the ...

Stifel projected that the 15-day sensor could enhance DexCom’s gross margin in 2026, potentially contributing to year-over-year EBITDA margin expansion. The firm acknowledged certain risks, including ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...

Bullish option flow detected in DexCom (DXCM) with 4,618 calls trading, 1.3x expected, and implied vol increasing almost 3 points to 63.76%. Dec-25 85 calls and 10/24 weekly 73 calls are the most ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.

Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...

Investing.com - Stifel resumed coverage of DexCom (NASDAQ:DXCM) with a Buy rating and set a price target of $85.00, according to a research note published Monday. The company, currently trading at $68 ...